55
Participants
Start Date
April 28, 2021
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine
One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine
One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
RECRUITING
Hvidovre Hospital, Hvidovre
Thomas Benfield
OTHER